In vitro activities of amphotericin B and voriconazole against aleurioconidia from Aspergillus terreus

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 6, 2005, Pages 2539-2540

  Lass Flörl, Cornelia ^a   Rief, Alexandra ^a   Leitner, Sandra ^a   Speth, Cornelia ^a   Würzner, Reinhard ^a   Dierich, Manfred P ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; VORICONAZOLE;

ALEURIOSPORE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS TERREUS; CONIDIUM; FUNGAL STRAIN; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; HUMANS; HYPHAE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 19544380234     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.6.2539-2540.2005     Document Type: Article

References (19)

1. Aisner, J., P. H. Wiernik, and S. C. Schimpff. 1977. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann. Intern. Med. 86:539-543.
2. Anaissie, E. 1992. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin. Infect. Dis. 46(Suppl. 1):43-53.
3. Böhme, A., M. Ruhnke, D. Buchheidt, M. Karthaus, H. Einsele, and H. Szelènyi. 2003. Treatment of fungal infections in hematology and oncology. Ann. Hematol. 82:133-140.
4. Denning, D. W. 1998. Invasive aspergillosis. Clin. Infect. Dis. 26:781-805.
5. Espinel-Ingroff, A., M. Bartlett, R. Bowden, N. X. Chin, C. Cooper, A. Fothergill, R. M. McGinnis, P. Menezes, S. A. Messer, P. W. Nelson, F. C. Odds, L. Pasarell, J. Peter, M. Pfaller, J. Rex, M. Rinaldi, G. S. Shankland, T. Walsh, and I. Weitzman. 1997. A multicenter evaluation of the standardization of antifungal susceptibility testing for filamentous fungi. J. Clin. Microbiol. 35:139-143.
6. Iwen, P. C., M. E. Rupp, A. N. Langnas, E. C. Reed, and S. H. Hinrichs. 1998. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-years experience and review of the literature. Clin. Infect. Dis. 26:1092-1097.
7. Lass-Flörl, C., P. M. Rath, D. Niederwieser, G. Kofler, R. Würzner, A. Kreczy, and M. P. Dierich. 2000. Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. J. Hosp. Infect. 46:31-35.
8. Lass-Flörl, C., M. Nagl, C. Speth, H. Ulmer, M. P. Dierich, and R. Würzner. 2001. Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob. Agents Chemother. 45:124-128.
9. Murphy, M., E. M. Bernard, T. Ishimaru, and D. Armstrong. 1997. Activity of voriconazole against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698.
10. National Committee for Clinical Laboratory Standards. 2002. Reference methods for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. Pannuti, C., R. Gingrich, M. Pfaller, C. Kao, and R. P. Wenzel. 1992. Nosocomial pneumonia in patients having bone marrow transplant: attributable mortality and risk factors. Cancer 69:2653-2662.
12. Russack, V. 1990. Aspergillus terreus myocarditis: report of a case and review of the literature. Am. J. Clin. Pathol. 3:275-279.
13. Steinbach, W., J. R. Perfect, W. A. Schell, T. J. Walsh, and D. K. Benjamin. 2004. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob. Agents. Chemother. 48:3217-3225.
14. Steinbach, W., D. K. Benjamin, D. P. Kontoyiannis, J. R. Perfect, I. Lutsar, K. A. Marr, M. S. Lionakis, H. A. Torres, H. Jafri, and T. J. Walsh. 2004. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin. Infect. Dis. 39:192-198.
15. Stevens, D., V. L. Kan, M. A. Judson, V. Morrison, S. Dummer, D. W. Dennind, D. Bennett, T. Walsh, T. F. Patterson, P. Pankey, et al. 2000. Practice guidelines for diseases caused by Aspergillus. Clin. Infect. Dis. 30:696-709.
16. Sutton, D. A., S. E. Sanche, S. G. Revankar, A. Fothergill, and M. Rinaldi. 1999. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J. Cin. Microbiol. 37:2343-2345.
17. Tritz, D. M., and G. L. Woods. 1993. Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts. Clin. Infect. Dis. 16:118-122.
18. Walsh, T., V. Petraitis, R. Petraitiene, A. Field-Ridely, D. A. Sutton, M. Ghannoum, T. Sein, R. Schaufele, J. Peter, J. Bacher, H. Casler, D. Armstrong, A. Espinel-Ingroff, M. Rinaldi, and C. A. Lyman. 2003. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. 188:305-319.
19. Walsh, T. J., and P. A. Pizzo. 1988. Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation. Annu. Rev. Microbiol. 42:517-545.